THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL

被引：0
|
作者：
Sweeney, Michael
Nicholls, Stephen J.
Ray, Kausik Kumar
Buhr, Kevin
Ginsberg, Henry
Johansson, Jan
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter
Wong, Norman
Schwartz, Gregory G.
机构：
[1] Imperial Coll, London, England
[2] Resverlogix Corp, Calgary, AB, Canada
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1315-168
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [1] Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    CIRCULATION, 2019, 140 (25) : E966 - E966
  • [2] Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry D.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Cummings, Jeffrey L.
    Sweeney, Michael
    Schwartz, Gregory G.
    AMERICAN HEART JOURNAL, 2019, 217 : 72 - 83
  • [3] Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes
    Ray, K. K.
    Nicholls, S. J.
    Buhr, K. A.
    Ginsberg, H. N.
    Kalantar-Zadeh, K.
    Johansson, J. O.
    Kulikowski, E.
    Toth, P. P.
    Wong, N.
    Sweeney, M.
    Schwartz, G. G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1425 - 1425
  • [4] BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING APABETALONE IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME
    Ray, Kausik K.
    Nicholls, Stephen
    Sweeney, Michael
    Johansson, Jan
    Wong, Norman
    Kulikowski, Ewelina
    Lebioda, Kenneth
    Toth, Peter
    Ginsberg, Henry
    Kalantar-Zadeh, Kamyar
    Haarhaus, Mathias L.
    Winblad, Bengt
    Cummings, Jeffrey L.
    Schwartz, Gregory
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1864 - 1864
  • [5] Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
    Stephen J. Nicholls
    Gregory G. Schwartz
    Kevin A. Buhr
    Henry N. Ginsberg
    Jan O. Johansson
    Kamyar Kalantar-Zadeh
    Ewelina Kulikowski
    Peter P. Toth
    Norman Wong
    Michael Sweeney
    Kausik K. Ray
    Cardiovascular Diabetology, 20
  • [6] Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
    Nicholls, Stephen J.
    Schwartz, Gregory G.
    Buhr, Kevin A.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [7] Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    CIRCULATION, 2020, 142
  • [8] Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome Results from the BETonMACE Randomized Controlled Trial
    Kalantar-Zadeh, Kamyar
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Buhr, Kevin A.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kulikowski, Ewelina
    Lebioda, Kenneth
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (05): : 705 - 716
  • [9] APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE, TYPE 2 DIABETES, AND RECENT ACUTE CORONARY SYNDROME: A BETONMACE TRIAL REPORT
    Kalantar-Zadeh, Kamyar
    Nicholls, Stephen J.
    Buhr, Kevin A.
    Ginsburg, Henry N.
    Johansson, Jan
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    Ray, Kausik K.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 819 - 819
  • [10] THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL
    Toth, Peter P.
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Johansson, Jan
    Ginsberg, Henry
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Wong, Norman C.
    Szarek, Michael
    Sweeney, Michael
    Ray, Kausik Kumar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1104 - 1104
12345